WORP VAN DER, H. B,, M. R. MACLEOD, P. M. W. BATH, R. BATHULA, H. CHRISTENSEN, B. COLAM, C. CORDONNIER, J. DEMOTES-MAINARD, I. DURAND-ZALESKI, C. GLUUD, J. C. JAKOBSEN, B. KALLMUNZERI, R. KOLLMAR, D. W. KRIEGER, K. R. LEES, D. MICHALSKI, C. MOLINA, J. MONTANER, R. O. ROINE, J. PETERSSON, R. PERRY, N. SPRIGG, D. STAYKOV, I. SZABO, G. VANHOOREN, J. M. WARDLAW, P. WINKEL, S. SCHWAB, S. SCHWAB, C. HOBOHM, H. SCHNEIDER, K. WARTENBERG, J. BERROUSCHOT, M. LORENZ, H. C. CHRISTENSEN, N. SPRIGG, R. BATHULA, P. FITZSIMMONS, R. PERRY, K. SAASTAMOINEN, B. C. CREAGH-BROWN, A. SWEENIE, R. LINDERT, M. RUBIERA, J. SERENAL, G. VANHOOREN, P. DESFONTAINES, C. CORDONNIER, I. SIBON, D. JATUZIS a F. ORZI. Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial. EUROPEAN STROKE JOURNAL. LONDON: SAGE PUBLICATIONS LTD, 2019, roč. 4, č. 3, s. 254-262. ISSN 2396-9873. Dostupné z: https://dx.doi.org/10.1177/2396987319844690.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial
Autoři WORP VAN DER, H. B,, M. R. MACLEOD, P. M. W. BATH, R. BATHULA, H. CHRISTENSEN, B. COLAM, C. CORDONNIER, J. DEMOTES-MAINARD, I. DURAND-ZALESKI, C. GLUUD, J. C. JAKOBSEN, B. KALLMUNZERI, R. KOLLMAR, D. W. KRIEGER, K. R. LEES, D. MICHALSKI, C. MOLINA, J. MONTANER, R. O. ROINE, J. PETERSSON, R. PERRY, N. SPRIGG, D. STAYKOV, I. SZABO, G. VANHOOREN, J. M. WARDLAW, P. WINKEL, S. SCHWAB, S. SCHWAB, C. HOBOHM, H. SCHNEIDER, K. WARTENBERG, J. BERROUSCHOT, M. LORENZ, H. C. CHRISTENSEN, N. SPRIGG, R. BATHULA, P. FITZSIMMONS, R. PERRY, K. SAASTAMOINEN, B. C. CREAGH-BROWN, A. SWEENIE, R. LINDERT, M. RUBIERA, J. SERENAL, G. VANHOOREN, P. DESFONTAINES, C. CORDONNIER, I. SIBON, D. JATUZIS a F. ORZI.
Vydání EUROPEAN STROKE JOURNAL, LONDON, SAGE PUBLICATIONS LTD, 2019, 2396-9873.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30210 Clinical neurology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Kód RIV RIV/00216224:14110/19:00121485
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1177/2396987319844690
UT WoS 000485316800007
Klíčová slova anglicky Ischaemic stroke; randomised trial; treatment; hypothermia; cooling
Štítky Excelence Science, FNUSA, RIV, rivok, Stroke, user
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 28. 4. 2021 09:48.
Anotace
Introduction We assessed whether modest systemic cooling started within 6 hours of symptom onset improves functional outcome at three months in awake patients with acute ischaemic stroke. Patients and methods In this European randomised open-label clinical trial with blinded outcome assessment, adult patients with acute ischaemic stroke were randomised to cooling to a target body temperature of 34.0-35.0 degrees C, started within 6 h after stroke onset and maintained for 12 or 24 h , versus standard treatment. The primary outcome was the score on the modified Rankin Scale at 91 days, as analysed with ordinal logistic regression. Results The trial was stopped after inclusion of 98 of the originally intended 1500 patients because of slow recruitment and cessation of funding. Forty-nine patients were randomised to hypothermia versus 49 to standard treatment. Four patients were lost to follow-up. Of patients randomised to hypothermia, 15 (31%) achieved the predefined cooling targets. The primary outcome did not differ between the groups (odds ratio for good outcome, 1.01; 95% confidence interval, 0.48-2.13; p = 0.97). The number of patients with one or more serious adverse events did not differ between groups (relative risk, 1.22; 95% confidence interval, 0.65-1.94; p = 0.52). Discussion In this trial, cooling to a target of 34.0-35.0 degrees C and maintaining this for 12 or 24 h was not feasible in the majority of patients. The final sample was underpowered to detect clinically relevant differences in outcomes. Conclusion Before new trials are launched, the feasibility of cooling needs to be improved.
Návaznosti
90090, velká výzkumná infrastrukturaNázev: CZECRIN II
VytisknoutZobrazeno: 8. 5. 2024 08:50